Edap Tms SA (NASDAQ:EDAP)

2.39
Delayed Data
As of May 25
 -0.01 / -0.42%
Today’s Change
2.07
Today|||52-Week Range
3.85
-16.72%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$70.8M

Company Description

EDAP TMS SA develops, produces and markets minimally invasive medical devices for urological diseases. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment, Ablatherm-HIFU is approved and commercialized in Europe as a treatment for prostate cancer and is currently under regulatory review in the U.S. In March 2013, the company introduced a new innovative HIFU device, the Focal One dedicated to focal therapy of prostate cancer. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.

Contact Information

EDAP TMS SA
Parc d'Activités la Poudrette-Lamart
Vaulx-en-Velin Rhone-alpes 69120
P:(347) 215-3150
Investor Relations:
(347) 826-4046

Employees

Shareholders

Other institutional7.08%
Mutual fund holders4.56%
Individual stakeholders--

Top Executives

Marc OczachowskiChief Executive Officer & Director
Francois DietschChief Financial Officer
Noah J. BartschVP-Global Medical Regulatory & Quality Affairs
Blandine ConfortInvestor Relations Officer